Unit 1 Flashcards
Window period of HIV
3 weeks to 6 months
Adverse effects with HIV to
Hepatotoxicity Nephrotoxicity Osteopenia Dyslipidemia Insulin resistance Increased CVD fat redistribution syndrome: Lipoatrophy: localized subQ fat loss in face, arms, legs and buttocks) Lipohypertrophy: central visceral fat accumulation in abdomen, breast, buffalo hump)
Viral set point
Remaining amount of virus in body after this initial immune response
Phase 1 HIV
primary infection (time from infection till the body makes antibodies) scary window (pt is contagious but doesnt show)
Acute Retroviral syndrome
fever lymphadenopathy pharyngitis skin rash myalgias
Phase 2 HIV
Asymptomatic
>500 CD4
Phase 3 HIV
symptomatic 200-499 CD4 Fever, chills, night sweats, diarrhea shingles cancer candidadis peripheral neuropathy PID
AIDS Phase 4 HIV
<14% lymphocyte count Candidadis (bronchi, trachea, etc) cervical cancer cryptococcosis Encephalopathy Herpes Simplex Kaposis sarcoma PCP wasting syndrome
EIA (enzyme immunoassay)
ID antibodies against HIV. Not definitive
Western blot assay
to confirm seropositivity when EIA result is positive
OraSure test
Uses saliva to perform EIA antibody (30 min) HIV screening
Tx of HIV infection based on
Viral load
CD4 count
clinical condition of pt
Tx for HIV if
T cell count 55000 (research says >100000)
Antiretrovirals S/E
Increased cholesterol DIabetes lipodystrophy facial wasting skinny arms and legs heart disease peripheral neuropathies thrombocytopenia depression
viral load testing every
and when else
3-4 months
before initiation and after 2-8 weeks
T cell counts every
3-6 months
Viral load undetectable
16-20 weeks
HAART
highly active antiretroviral therapy
Immunomodulator therapy
enhancement of the host immune response (interferons and colony-stimulating factors)
Clinical manifestations (HIV)
PCP MAC TB Oral candidiasis Wasting syndrome Kaposis sarcome B-cell lymphomas HIV encephalopathy Cryptococcus neoforms progressive multifocal leukoencephalopathy CMV MTB Toxopasmagondi
